Patents by Inventor Mark A. Varney
Mark A. Varney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11974992Abstract: The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonist.Type: GrantFiled: January 27, 2022Date of Patent: May 7, 2024Assignees: Neurolixis, The Regents of the University of CaliforniaInventors: Adrian Newman-Tancredi, Mark A. Varney, Khaleelurrahman Abdulrazak, Xin Tao
-
Publication number: 20230233539Abstract: The present application concerns the treatment and prevention of diseases associated with an increased risk of sudden unexpected death in epilepsy, such as Fragile X syndrome, by administering a selective 5-HT1A receptor agonistType: ApplicationFiled: January 27, 2022Publication date: July 27, 2023Inventors: Adrian Newman-Tancredi, Mark A. Varney, Khaleelurrahman Abdulrazak, Xin Tao
-
Patent number: 10562878Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.Type: GrantFiled: December 8, 2017Date of Patent: February 18, 2020Assignee: SUNOVION PHARAMCEUTICALS INC.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campell
-
Patent number: 9868718Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.Type: GrantFiled: September 30, 2014Date of Patent: January 16, 2018Assignee: Sunovion Pharmaceuticals Inc.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
-
Patent number: 9586888Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.Type: GrantFiled: January 7, 2014Date of Patent: March 7, 2017Assignee: SUNOVION PHARMACEUTICALS INC.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
-
Patent number: 8877975Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.Type: GrantFiled: January 15, 2010Date of Patent: November 4, 2014Assignee: Sunovion Pharmaceuticals Inc.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
-
Patent number: 8669291Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.Type: GrantFiled: June 2, 2008Date of Patent: March 11, 2014Assignee: Sunovion Pharmaceuticals Inc.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
-
Publication number: 20120123164Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Judy CARON, Thomas Wessel, Karim Lalji, Mark A. Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Steve Han, Stefan G. Koenig
-
Patent number: 8053603Abstract: The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.Type: GrantFiled: December 21, 2006Date of Patent: November 8, 2011Assignee: Sunovion Pharmaceuticals Inc.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Jianguo Ma
-
Patent number: 7884124Abstract: This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.Type: GrantFiled: July 2, 2007Date of Patent: February 8, 2011Assignee: Sepracor Inc.Inventors: Michele L. R. Heffernan, Robert J. Foglesong, Seth C. Hopkins, Mustapha Soukri, Steven W. Jones, Kerry L. Spear, Mark A. Varney
-
Publication number: 20100190861Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.Type: ApplicationFiled: January 15, 2010Publication date: July 29, 2010Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
-
Publication number: 20090111817Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.Type: ApplicationFiled: July 5, 2006Publication date: April 30, 2009Applicant: SEPRACOR INC.Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney
-
Publication number: 20090111818Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.Type: ApplicationFiled: July 5, 2006Publication date: April 30, 2009Applicant: SEPRACOR INC.Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney
-
Publication number: 20090005456Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.Type: ApplicationFiled: June 2, 2008Publication date: January 1, 2009Applicant: SEPRACOR INC.Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
-
Publication number: 20080293726Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.Type: ApplicationFiled: July 6, 2006Publication date: November 27, 2008Applicant: SEPRACOR INC.Inventors: Judy Caron, Thomas Wessel, Karim Lalji, Mark A. Varney, Roger P. Bakale, Surendra P. Singh, H. Scott Wilkinson, Xiping Su, Zhengxu Steve Han, Stefan G. Koenig
-
Publication number: 20080175903Abstract: The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.Type: ApplicationFiled: December 1, 2007Publication date: July 24, 2008Applicant: Sepracor Inc.Inventors: Seth C. Hopkins, Mark A. Varney, Tushar Misra, Gary Maier, Judy Caron, Randall S. Wagner
-
Patent number: 6956049Abstract: In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds.Type: GrantFiled: August 31, 1999Date of Patent: October 18, 2005Assignee: Merck & Co., Inc.Inventors: Nicholas D. P. Cosford, Ian A. McDonald, Stephen D. Hess, Mark A. Varney